Disc Medicine (NASDAQ:IRON) Stock Price Target Raised at Morgan Stanley

Disc Medicine (NASDAQ:IRON – Get Free Report) had its price target upped by research analysts at Morgan Stanley from $92.00 to $104.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley‘s price target would indicate a potential upside of 33.84% from the stock’s current price.

IRON has been the topic of a number of other research reports. Cantor Fitzgerald lifted their target price on Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a research report on Monday, October 19th. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Jefferies Financial Group restated a “buy” rating and issued a $149.00 price target on shares of Disc Medicine in a research note on Wednesday, October 21st. BMO Capital Markets lifted their price target on shares of Disc Medicine from $100.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, October 19th. Finally, Guggenheim started coverage on shares of Disc Medicine in a research report on Monday, November 9th. They set a “buy” rating and a $132.00 price objective for the company. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus price target of $125.27.

Get Our Latest Analysis on IRON

Disc Medicine Price Performance

Shares of IRON stock traded up $1.14 during trading hours on Wednesday, reaching $77.71. The company’s stock had a trading volume of 75,796 shares, compared to its average volume of 676,511. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The firm’s 50 day simple moving average is $71.54 and its 200-day simple moving average is $71.04. The company has a quick ratio of 20.30, a current ratio of 20.30 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -12.18 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.10. Sell-side analysts forecast that Disc Medicine will post -6.20 earnings per share for the current year.

Insider Activity at Disc Medicine

In related news, Director Kevin Bitterman sold 25,519 shares of the business’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $80.23, for a total transaction of $2,047,389.37. Following the sale, the director owned 12,991 shares in the company, valued at $1,042,267.93. The trade was a 66.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William Savage sold 16,035 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $85.09, for a total value of $1,364,418.15. Following the sale, the insider owned 63,445 shares in the company, valued at $5,398,535.05. This represents a 20.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 150,277 shares of company stock valued at $11,877,059 in the last 90 days. 3.76% of the stock is owned by corporate insiders.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently made changes to their positions in IRON. BlackRock Inc. acquired a new position in shares of Disc Medicine in the second quarter valued at approximately $180,502,000. Wellington Management Group LLP raised its holdings in Disc Medicine by 0.3% in the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock valued at $127,362,000 after buying an additional 5,975 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Disc Medicine by 191.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after buying an additional 735,300 shares during the period. Opaleye Management Inc. boosted its position in Disc Medicine by 103.1% during the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after buying an additional 434,000 shares during the period. Finally, Aberdeen Group plc boosted its position in Disc Medicine by 36.4% during the 3rd quarter. Aberdeen Group plc now owns 597,841 shares of the company’s stock worth $39,135,000 after buying an additional 159,667 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Company Profile

(Get Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Further Reading

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.